ARTICLE | Management Tracks
Syncona-backed Forcefield names Novartis vet Tsai CEO
Plus: PureTech hires Arix CEO Lyne and updates from InterVenn, Veracyte, Arcutis, Strata, Sanotize, Caribou, Mati
September 27, 2023 11:45 PM UTC
John Tsai will become CEO of Forcefield Therapeutics Ltd., a Syncona Ltd. (LSE:SYNC) portfolio company that is developing therapeutics to retain heart function via protection of cardiomyocytes. Tsai, an executive partner at Syncona, was most recently president, global drug development and CMO at Novartis AG (SIX:NOVN; NYSE:NVS).
PureTech Health plc (LSE:PRTC; NASDAQ:PRTC) hired Robert Lyne as chief portfolio officer. Lyne joins from Arix Bioscience plc (LSE:ARIX), where he was CEO...